Vasopressin is secreted by posterior pituitary and act as an antidiuretic hormone the function of vasopressin is to maintain the osmolarity of urine. It is a peptide hormone which acts as an antidiuretic hormone. It reduces the excretion of water and electrolyte in urine and. Vasopressin has an important role in diabetes insipidus. Diabetes insipidus is an uncommon disorder of water and electrolyte imbalance in which large volume of diluted urine is excreted abnormally from body which is known as polyurea and there is increase in intake of fluid which is known as polydipsia. The production of vasopressin is insufficient sometimes due to various reasons such as its increased degradation and impaired response of kidney to vasopressin, and due to this impaired production of vasopressin, a disease is occur which is known as DI. Patient with more severity and have uncompensated symptoms can develop various disorders such as marked dehydration, neurologic symptoms, encephalopathy etc. So if diabetes insipidus is not controlled by properly diagnosed and managed it can be a life-threatening disorder. Patients with diabetes insipidus can be treated with vasopressin and desmopressin. We review here current knowledge on the different aspects such as pathophysiology, classification, clinical presentation, diagnosis and management of DI.
Cite this article:
Shivani Chib, Neha Kumari, Sukhbinder. Role of Vasopressin and Desmopressin in Diabetes Insipidus. Int. J. Tech. 2020; 10(1):7-12. doi: 10.5958/2231-3915.2020.00002.4
1. Cuzzo B, Lappin SL. Vasopressin (antidiuretic hormone, ADH). InStatPearls [Internet] 2019 Feb 2. StatPearls Publishing.
2. StatPearlsPublishingGarrahy A, Thompson CJ. Vasopressin.
3. Robertson GL. Physiology of ADH secretion. Kidney international supplement. 1987 Aug 2(21).
4. Verbalis JG. Disorders of water metabolism: diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion. InHandbook of clinical neurology 2014 Jan 1 (Vol. 124, pp. 37-52). Elsevier.
5. Thrasher TN. Baroreceptor regulation of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Frontiers in neuroendocrinology. 1994 Jun 1;15(2):157-96.
6. Wang O, Majzoub JA. Adrenocorticotropin. InThe pituitary 2011 Jan 1 (pp. 47-81). Academic Press.
7. Majzoub JA, Srivatsa A. Diabetes insipidus: clinical and basic aspects. Pediatric endocrinology reviews: PER. 2006 Dec; 4:60-5.
8. Sharman A, Low J. Vasopressin and its role in critical care. Continuing Education in Anaesthesia Critical Care and Pain. 2008 Aug 1;8(4):134-7.
9. Qureshi S, Galiveeti S, Bichet DG, Roth J. Diabetes insipidus: celebrating a century of vasopressin therapy. Endocrinology. 2014 Dec 1;155(12):4605-21.
10. Kalra S, Zargar AH, Jain SM, Sethi B, Chowdhury S, Singh AK, Thomas N, Unnikrishnan AG, Thakkar PB, Malve H. Diabetes insipidus: The other diabetes. Indian journal of endocrinology and metabolism. 2016 Jan;20(1):9.
11. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes spectrum. 2004 Jul 1;17(3):183-90.
12. Saborio P, Tipton GA, Chan JC. Diabetes insipidus. Pediatrics in review. 2000 Apr 1;21(4):122-9.
14. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nature Reviews Nephrology. 2015 Oct;11(10):576-88.
15. Vincent JL, Su F. Physiology and pathophysiology of the vasopressinergic system. Best practice and research Clinical anaesthesiology. 2008 Jun 1;22(2):243-52.
16. Robertson GL. Diabetes insipidus: differential diagnosis and management. Best Practice and Research Clinical Endocrinology and Metabolism. 2016 Mar 1;30(2):205-18.
18. Crawford JD, Kennedy GC. Chlorothiazid in diabetes insipidus. Nature. 1959 Mar;183(4665):891-2.
19. Robinson AG. DDAVP in the treatment of central diabetes insipidus. New England Journal of Medicine. 1976 Mar 4;294(10):507-11.
20. Lukitsch I, Pham TQ. eMedicine Specialties> Nephrology> Acid-Base, Fluid, and Electrolyte Disorders.
21. Cobb WE, Spare S, Reichlin S. Neurogenic diabetes insipidus: management with dDAVP (1-desamino-8-D arginine vasopressin). Annals of internal medicine. 1978 Feb 1;88(2):183-8.
22. Saini NK, Singhal M, Srivastava B. Diabetes Insipidus (Drug Treatment and Animal Models): A Review.
23. Harris AS. Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions. The Journal of pediatrics. 1989 Apr 1;114(4):711-8.
24. Robertson GL. Diabetes insipidus. Endocrinology and metabolism clinics of North America. 1995 Sep 1;24(3):549-72.
25. Holt NF, Haspel KL. Vasopressin: a review of therapeutic applications. Journal of cardiothoracic and vascular anesthesia. 2010 Apr 1;24(2):330-47.
26. Kumar P. An experimental study to assess the effectiveness of structured teaching programme on knowledge regarding the management of diabetes mellitus. Asian journal of management; 2014; 3(5): 329-331.
27. Kaur H. Effective of structured teaching programme regarding self-care management in relation to prevention of complications among diabetics. Asian journal of nursing education and research; 2014; 3(4) : 279-283.
28. Kumar P. The effectiveness of structured teaching programme on knowledge regarding the diabetes mellitius. Asian journal of nursing education and reseach; 2014; 3(4): 304-306.